Restless Legs Syndrome - Drug Pipeline Landscape, 2023
Description
Restless Legs Syndrome - Drug Pipeline Landscape, 2023
Restless Legs Syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move one's legs. The exact cause of RLS is unknown, but it is thought to be associated with a dysfunction in the brain's dopamine system. This system is responsible for regulating movement and is also involved in the feeling of pleasure and reward. RLS is thought to be caused by a combination of genetic and environmental factors. Other conditions that contribute to RLS include low levels of iron (iron deficiency), uremia, hypothyroidism, depression, fibromyalgia and Parkinson's disease.
Symptoms of RLS include leg (or arm) discomfort, urge to move legs, sleep disruption, bedtime behavior problems and daytime sleepiness.
Healthcare provider may conduct a physical and a neurological exam. Other tests like blood tests may be recommended.
Restless legs syndrome can be treated with non-drug treatments like regular exercise, good sleeping habits and iron supplementation prescription medications like dopamine agonists and anti-seizure medications.
RLS is a relatively common disorder, affecting up to 10% of the population. It is more common in women and people of European descent. RLS is often associated with other conditions, such as iron deficiency, pregnancy, and certain neurological disorders.
There is no cure for RLS, but treatments are available to help relieve the symptoms. These include dopaminergic medications, iron supplements, and lifestyle changes.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Restless legs syndrome, such as LY03009 and others. Key players involved in the development of therapies to treat restless legs syndrome are Eli Lilly and Co., Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb, and others. Three drugs are in Phase I and some other drugs in preclinical stage of development.
Report Highlights
Global Insight Service's, Restless Legs Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Restless Legs Syndrome pipeline drugs. This report covers detailed insights on Restless Legs Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Restless Legs Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Restless Legs Syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move one's legs. The exact cause of RLS is unknown, but it is thought to be associated with a dysfunction in the brain's dopamine system. This system is responsible for regulating movement and is also involved in the feeling of pleasure and reward. RLS is thought to be caused by a combination of genetic and environmental factors. Other conditions that contribute to RLS include low levels of iron (iron deficiency), uremia, hypothyroidism, depression, fibromyalgia and Parkinson's disease.
Symptoms of RLS include leg (or arm) discomfort, urge to move legs, sleep disruption, bedtime behavior problems and daytime sleepiness.
Healthcare provider may conduct a physical and a neurological exam. Other tests like blood tests may be recommended.
Restless legs syndrome can be treated with non-drug treatments like regular exercise, good sleeping habits and iron supplementation prescription medications like dopamine agonists and anti-seizure medications.
RLS is a relatively common disorder, affecting up to 10% of the population. It is more common in women and people of European descent. RLS is often associated with other conditions, such as iron deficiency, pregnancy, and certain neurological disorders.
There is no cure for RLS, but treatments are available to help relieve the symptoms. These include dopaminergic medications, iron supplements, and lifestyle changes.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Restless legs syndrome, such as LY03009 and others. Key players involved in the development of therapies to treat restless legs syndrome are Eli Lilly and Co., Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb, and others. Three drugs are in Phase I and some other drugs in preclinical stage of development.
Report Highlights
Global Insight Service's, Restless Legs Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Restless Legs Syndrome pipeline drugs. This report covers detailed insights on Restless Legs Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Restless Legs Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
54 Pages
- 1. Introduction
- 1.1 Restless Legs Syndrome - Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview - Restless Legs Syndrome
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Restless Legs Syndrome - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs - Phase I
- 5.1.1 EBS-101
- 5.1.2 LY 03009
- 5.2.1 OMS 527
- 5.2 Early Stage Drugs - Preclinical
- 5.2.1 Cannabidiol and Gabapentin Chewing Gum
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Axim Biotechnologies Inc
- 9.2 Emalex Biosciences Inc
- 9.3 Luye Pharma Group
- 9.4 Omeros Corp
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2. 1 Clinical Trial Details - LY 03009/Luye Pharma Group
- Table 2. 2 Clinical Trial Details - OMS 527/Omeros Corp
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4. 2 Discontinued Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Restless Legs Syndrome, 2023
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Restless Legs Syndrome, 2023
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Restless Legs Syndrome, 2023
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Restless Legs Syndrome, 2023
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Restless Legs Syndrome, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
